Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

被引：6

作者：

Usmani, Saad Z. ^{[1
]}

Nahi, Hareth ^{[2
]}

Mateos, Maria-Victoria ^{[3
]}

Lokhorst, Henk M. ^{[4
]}

Chari, Ajai ^{[5
]}

Kaufman, Jonathan L. ^{[6
]}

Moreau, Philippe ^{[7
]}

Oriol, Albert ^{[8
]}

Plesner, Torben ^{[9
,10
,11
]}

Benboubker, Lotfi ^{[12
]}

Hellemans, Peter ^{[13
]}

Masterson, Tara ^{[14
]}

Clemens, Pamela L. ^{[15
]}

Ahmadi, Tahamtan ^{[15
]}

Liu, Kevin ^{[16
]}

San-Miguel, Jesus ^{[17
]}

机构：

[1] Levine Canc Inst Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[2] Karolinska Univ Hosp, Karolinska Inst, Div Hematol, Huddinge, Sweden

[3] Univ Hosp Salamanca IBSAL, Salamanca, Spain

[4] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[5] Tisch Canc Inst, Mt Sinai Sch Med, New York, NY USA

[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[7] Nantes Univ Hosp, Dept Hematol, Nantes, France

[8] HGTiP, Inst Catala Oncol, Barcelona, Spain

[9] Univ So Denmark, Vejle Hosp, Ctr Little Belt, Dept Hematol, Vejle, Denmark

[10] Vejle Hosp, Dept Hematol, Vejle, Denmark

[11] Univ So Denmark, Vejle, Denmark

[12] CHU Tours Hop Bretonneau, Tours, France

[13] Janssen Res & Dev, Beerse, Belgium

[14] Janssen Res & Dev, Spring House, PA USA

[15] Janssen Res & Dev, LLC, Spring House, PA USA

[16] Janssen Res & Dev, LLC, Raritan, NJ USA

[17] Clin Univ Navarra CIMA, IDISNA, Pamplona, Spain

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1149.1149

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1149

引用

页数：6

共 50 条

[1] Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
Chari, Ajai
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Liu, Kevin
San-Miguel, Jesus F.
Usmani, Saad Z.
BLOOD, 2017, 130
[2] SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)
Mateos, M., V
Chari, A.
Nah, H.
Lokhorst, H.
Kaufman, J. L.
Moreau, P.
Oriol, A.
Plesner, T.
Benboubker, L.
Hellemans, P.
Masterson, T.
Clemens, P. L.
Liu, K.
San-Miguel, J.
Usmani, S. Z.
HAEMATOLOGICA, 2018, 103 : 32 - 33
[3] Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
Chari, Ajai
Usmani, Saad Zafar
Mateos, Maria-Victoria
Van De Donk, Niels
Kaufman, Jonathan L.
Moreau, Philippe
Rocafiguera, Albert Oriol
Plesner, Torben
Benboubker, Lotfi
Liu, Kevin
Hellemans, Peter
Masterson, Tara J.
Clemens, Pamela L.
Farnsworth, Andrew
Nahi, Hareth
San-Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
San-Miguel, Jesus
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Liu, Kevin
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Luo, Man
Farnsworth, Andrew
Nahi, Hareth
Chari, Ajai
HAEMATOLOGICA, 2021, 106 (06) : 1725 - 1732
[5] Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Chari, Ajai
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Nahi, Hareth
Tang, Jie
Hellemans, Peter
Tromp, Brenda
Clemens, Pamela L.
Farnsworth, Andrew
San-Miguel, Jesus F.
Usmani, Saad Z.
BLOOD, 2018, 132
[6] Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study
Nahi, Hareth
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Bandyopadhyay, Nibedita
Hellemans, Peter
Tromp, Brenda
Nnane, Ivo
Zemlickis, Donna
Farnsworth, Andrew
Chari, Ajai
BLOOD, 2021, 138
[7] An open-label, dose-escalation phase lb study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO).
Nahi, Hareth
Hellemans, Peter
Masterson, Tara J.
Clemens, Pamela L.
Ahmadi, Tahamtan
San Miguel, Jesus
Mateos, Maria-Victoria
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study
Nahi, Hareth
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Oriol, Albert
Plesner, Torben
Bandyopadhyay, Nibedita
Hellemans, Peter
Tromp, Brenda
Nnane, Ivo
Zemlickis, Donna
Chari, Ajai
Moreau, Philippe
LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 468 - 472
[9] Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Clemens, Pamela L.
Xu, Steven
Luo, Melody
Chari, Ajai
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
San-Miguel, Jesus F.
Sun, X. Yu-Nien
Farnsworth, Andrew
Masterson, Tara
Hellemans, Peter
Qi, Ming
Nahi, Hareth
BLOOD, 2018, 132
[10] Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)
An, Gang
Ge, Zheng
Jing, Hongmei
Liu, Jing
Yang, Guoping
Feng, Ru
Xu, Zhongyuan
Qi, Ming
Wang, Jianping
Song, Juanjuan
Zhou, Wei
Sun, Binbin
Zhu, Dian
Chen, Xi
Cui, Canchan
Qiu, Lugui
BLOOD SCIENCE, 2024, 6 (03): : e00193

← 1 2 3 4 5 →